Sight Sciences, Inc. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Sight Sciences, Inc. filed its Q1 2024 10-Q report, detailing financial positions and a recent litigation settlement.</b>

AI Summary

Sight Sciences, Inc. (SGHT) filed a Quarterly Report (10-Q) with the SEC on May 6, 2024. Sight Sciences, Inc. filed a 10-Q report for the period ending March 31, 2024. The filing covers the first quarter of fiscal year 2024. Key financial statement items and dates are referenced, including Retained Earnings, Common Stock, and various credit agreements. The company's business address is 4040 Campbell Ave, Suite 100, Menlo Park, CA 94025. A subsequent event on April 26, 2024, involved a settled litigation with royalty damages.

Why It Matters

For investors and stakeholders tracking Sight Sciences, Inc., this filing contains several important signals. This 10-Q filing provides investors with the latest financial performance and position of Sight Sciences, Inc. for the first quarter of 2024, crucial for evaluating investment decisions. The mention of a settled litigation with royalty damages on April 26, 2024, is a significant event that could impact the company's financial health and future operations.

Risk Assessment

Risk Level: low — Sight Sciences, Inc. shows low risk based on this filing. The filing is a standard quarterly report (10-Q) with no immediate indicators of significant financial distress or major operational shifts beyond routine disclosures and a settled litigation.

Analyst Insight

Monitor future filings for detailed financial results and the impact of the settled litigation on the company's profitability and cash flow.

Key Numbers

• 2024-03-31 — Period End Date (Reporting period for the 10-Q)
• 2024-05-06 — Filing Date (Date the 10-Q was filed)
• 2024-01-01 — Quarter Start Date (Beginning of the reporting quarter)
• 2023-03-31 — Prior Year Quarter End (End of the comparable prior year quarter)

Key Players & Entities

• Sight Sciences, Inc. (company) — Filer name
• 4040 Campbell Ave, Suite 100, Menlo Park, CA 94025 (address) — Business and mailing address
• 2024-03-31 (date) — Period of report
• 2024-05-06 (date) — Filing date
• 2024-04-26 (date) — Date of settled litigation

FAQ

Risk Factors

• Settled Litigation [medium — legal]: The company was involved in a settled litigation with royalty damages on April 26, 2024, which is disclosed as a subsequent event.

Industry Context

Sight Sciences, Inc. operates in the surgical and medical instruments & apparatus industry, focusing on ophthalmic medical devices.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, requiring regular reporting of financial and operational information to the SEC.

What Investors Should Do

1. Review the full 10-Q filing for detailed financial statements and management's discussion and analysis.
2. Investigate the specifics and financial implications of the settled litigation mentioned as a subsequent event.
3. Track Sight Sciences' performance in subsequent quarters to assess the impact of Q1 results and any ongoing operational or legal developments.

Key Dates

• 2024-03-31: Quarterly Period End — Marks the end of the reporting period for the 10-Q.
• 2024-05-06: Filing Date — Date the 10-Q was officially submitted to the SEC.
• 2024-04-26: Settled Litigation — A significant subsequent event impacting the company.

Year-Over-Year Comparison

This is the initial 10-Q filing for the period ending March 31, 2024, as indicated by the filing date and the absence of prior period comparative data within the provided snippet.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share SGHT The Nasdaq Global Se

Filing Documents

• sght-20240331.htm (10-Q) — 1312KB
• sght-ex31_1.htm (EX-31.1) — 20KB
• sght-ex31_2.htm (EX-31.2) — 20KB
• sght-ex32_1.htm (EX-32.1) — 10KB
• sght-ex32_2.htm (EX-32.2) — 9KB
• 0000950170-24-053572.txt (&nbsp;) — 6879KB
• sght-20240331.xsd (EX-101.SCH) — 1345KB
• sght-20240331_htm.xml (XML) — 1030KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 29 Item 4.

Controls and Procedures

Controls and Procedures 29 PART II. OTHER INFORMATION 29 Item 1.

Legal Proceedings

Legal Proceedings 29 Item 1A.

Risk Factors

Risk Factors 30 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 32 Item 3. Defaults Upon Senior Securities 32 Item 4. Mine Safety Disclosures 32 Item 5. Other Information 32 Item 6. Exhibits 33

Signatures

Signatures 34 2 SPECIA L NOTE REGARDING FORWARD-LOOKING STATEMENTS Unless the context otherwise requires, references in this Quarterly Report on Form 10-Q to the "Company," "Sight Sciences," "we," "us" and "our" refer to Sight Sciences, Inc. This Quarterly Report on Form 10-Q for the fiscal period ended March 31, 2024 (this "Quarterly Report") contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "hope," "intend," "may," "might," "objective," "ongoing," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. These forward-looking statements include, but are not limited to, statements concerning the following: our ability to obtain and maintain sufficient reimbursement for our products, including our ability to successfully protect reimbursement for our Surgical Glaucoma products; estimates of our total addressable market, future revenue, expenses, capital requirements, and our needs for additional financing; our ability to enter into and compete in new markets; our ability to compete effectively with existing competitors and new market entrants

Financial Statements

Item 1. Financial Statements SIGHT SCIENCES, INC. Condensed Consolidated Balan ce Sheets (Unaudited) (in thousands, except share and per share data) March 31, December 31, 2024 2023 Assets Current assets: Cash and cash equivalents $ 127,284 $ 138,129 Accounts receivable, net of allowance for credit losses of $ 1,019 and $ 1,186 at March 31, 2024 and December 31, 2023, respectively 15,643 14,289 Inventory, net 6,871 7,849 Prepaid expenses and other current assets 2,291 2,604 Total current assets 152,089 162,871 Property and equipment, net 1,550 1,640 Operating lease right-of-use assets 1,297 1,458 Other noncurrent assets 624 682 Total assets $ 155,560 $ 166,651 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 1,666 $ 1,731 Accrued compensation 4,028 4,528 Accrued and other current liabilities 5,999 3,774 Current portion - long-term debt, net — 2,219 Total current liabilities 11,693 12,252 Long-term debt 33,697 31,708 Other noncurrent liabilities 961 2,476 Total liabilities 46,351 46,436 Commitments and contingencies (Note 6) Stockholders' equity: Preferred stock, par value $ 0.001 per share; 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2024 and December 31, 2023 — — Common stock, par value $ 0.001 per share; 200,000,000 shares authorized; 49,565,200 and 49,131,363 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively 50 49 Additional paid-in-capital 420,215 414,956 Accumulated deficit ( 311,056 ) ( 294,790 ) Total stockholders' equity 109,209 120,215 Total liabilities and stockholders' equity $ 155,560 $ 166,651 The accompanying notes are an integral part of these condensed consolidated financial statements. 5 SIGHT SCIENCES, INC. Condensed Consoli dated Statements of Operations and Co

View Full Filing

View this 10-Q filing on SEC EDGAR